Clinical trial of phototherapy and vorinostat in the treatment of cutaneous T-cell lymphoma
Not Applicable
Recruiting
- Conditions
- Cutaneous T-cell lymphoma
- Registration Number
- JPRN-UMIN000010246
- Lead Sponsor
- Department of Dermatology, Okayama University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. women who were pregnant or lactating or those having known central nervous system involvement or any other malignant disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the synergy between phototherapy and vorinostat in cutaneous T-cell lymphoma?
How does the combination of phototherapy and vorinostat compare to standard-of-care treatments for mycosis fungoides and Sézary syndrome?
Which biomarkers are associated with response prediction to phototherapy and vorinostat in CTCL patients?
What are the known adverse events and management strategies for phototherapy combined with HDAC inhibitors like vorinostat in CTCL?
Are there other HDAC inhibitors or combination approaches being investigated alongside phototherapy for cutaneous T-cell lymphoma treatment?